About

FluoGuide A/S is a clinical stage biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North

Board of directors

Shomit Ghose - Member of the board FluoGuide

Shomit Ghose

Member of the board

Shomit Ghose is an adjunct professor in entrepreneurship at the University of San Francisco and lecturer in engineering at UC Berkeley.  He was most recently Managing Director and General Partner at Silicon Valley venture fund ONSET Ventures, which he joined in 2001, and where he led the fund’s investing in data-driven start-ups for more than 20 years. He is a seasoned technology executive and a venture capitalist with technology operating experience. In addition to his time as an investor, he has 19 years of executive experience at high-tech companies in the Silicon Valley. Shomit Ghose specializes in the information technology sector with a focus on software, networking and infrastructure. He has been instrumental in several IPOs. Shomit Ghose holds a degree in Computer Science from the University of California Berkeley.

Born in 1961. Board member since 2019

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 21,143 and 0 warrants

 

 

Micaela Sjökvist - Member of the board FluoGuide

Micaela Sjökvist

Member of the board

Micaela Sjökvist is Head of Investor Relations at Securitas AB, a public listed company active in the security sector. Sjökvist has over 20 years of experience within corporate communications, financial communications and investor relations in listed international companies. Previous experience includes operative roles at both the international PR consultancy company Grayling and Telia Sonera AB. Micaela Sjökivst holds a B.Sc in Economics and Business Administration from Uppsala University.

Born in 1970. Board member since 2018

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 62,163 and 0 warrants

Peter Mørch Eriksen - Chairman of the board FluoGuide

Peter Mørch Eriksen

Chairman of the board

Peter Mørch Eriksen has more than 20 years of experience within medtech/life science both in Denmark and abroad. Peter Mørch Eriksen has been CEO of BioPorto A/S until 2021, and is now board member of BioPorto A/S, Peter Mørch Eriksen has been the CEO of Sense A/S and before this, he held positions as Vice President of Medtronic in both the USA and Denmark. From these positions Peter Mørch Eriksen brings extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. Peter Mørch Eriksen has an accounting background supplemented with courses in management. In addition to being Board member of BioPorto A/S, Peter Mørch Eriksen chairs the board of MTIC, is a board member at Nervex A/S, member of Lund University Advisory Board, and Director of PMEconsult ApS. He also serves on the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US.

Born in  1960. Chairman of the board since 2021

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of  FluoGuide shares 117,297 and 50,000 warrants (Partly owned via PME Holding ApS)

Andreas Kjaer - member of the board FluoGuide

Andreas Kjaer

member of the board

Andreas Kjaer, is an MD, PhD, DMSc and professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET and PET/MRI in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published more than 400 peer-review articles and has received numerous prestigious scientific awards over the years. Andreas Kjaer also has an MBA from Copenhagen Business School.

Born in  1963. Board member since 2018.

Number of FluoGuide shares  2,126,107 (owned via Life Science IVS) and privately 100,000 warrants .

 

Mats Thorèn - Vice chairman of the board FluoGuide

Mats Thorèn

Vice chairman of the board

Mats Thorén has 25 years of experience from the financial markets, where he has worked in the Healthcare both as an equity analyst and in corporate finance. For the past seventeen years, Mats Thorén has been a Healthcare investment professional. He has worked with Nalka Life Science AB and MedCap AB and now manages his own company, Vixco Capital, with a focus on investments. He currently serves on the boards of Xbrane BioPharma AB (Stockholm Smallcap), Arcoma AB (Stockholm First North) and Herantis Pharma Oy (Stockholm and Helsinki First North). He has previous board experience from C-Rad AB (Stockholm First North), as well as Cellartis AB, Duocort AB, MIP Technologies AB and several other private companies. Mats Thorén has studied at the Stockholm School of Economics focusing on Accounting and Financial Economics as well as studies in medicine at the Karolinska Institute in Stockholm.

Born in 1971. Board member since 2021

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 1,216 and 0 warrants